(Q42222473)

18 October 2017

title

Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes (English)

1 reference

18 October 2017

1 reference

1 reference

hepatitis E virus

1 reference

10

Ningshao Xia

1 reference

18 October 2017

Minxi Wei

1

1 reference

18 October 2017

Xiao Zhang

2

1 reference

18 October 2017

Hai Yu

3

1 reference

18 October 2017

Zi-Min Tang

4

1 reference

18 October 2017

Kaihang Wang

5

1 reference

18 October 2017

Zhongyi Li

6

1 reference

18 October 2017

Zizheng Zheng

7

1 reference

18 October 2017

Shaowei Li

8

1 reference

18 October 2017

Jun Zhang

9

1 reference

18 October 2017

Qinjian Zhao

11

1 reference

18 October 2017

language of work or name

English

0 references

publication date

22 March 2014

1 reference

18 October 2017

1 reference

18 October 2017

volume

32

1 reference

18 October 2017

issue

24

1 reference

18 October 2017

page(s)

2859-2865

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

18 October 2017

1 reference

Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Safety and efficacy of a recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Dimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host Interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Structural basis for the neutralization and genotype specificity of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.025

10.1016/J.VACCINE.2014.02.025

7 January 2021

Identifiers

DOI

1 reference

18 October 2017

1 reference